A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Trial Profile

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 9ER
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 21 Apr 2023 to 22 Apr 2023.
    • 12 Feb 2018 Enrollment to the triplet arm was discontinued by protocol amendment
    • 12 Feb 2018 Planned number of patients changed from 1014 to 630.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top